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Abstract
Background—We assembled a prospective cohort of 3144 children less than 15 years of age 
initiating ART in Dar es Salaam, Tanzania.
Methods—The relationships of nutritional status and other baseline characteristics in relation to 
mortality were examined using Cox proportional hazards model.
Results—Compared with children with weight for age (WAZ) >−1, those with WAZ ≤−2 to <−3 
had a nearly double risk of death (RR, 1.85 (95% CI, 1.10–3.11), and among those with WAZ ≤
−3, the risk more than tripled (RR, 3.36 (95% CI, 2.12–5.32). Other baseline risk factors for 
overall mortality included severe anemia (P<0.001), severe immune suppression (P=0.02), history 
of tuberculosis (P=0.01), opportunistic infections (P<0.001), living in the poorest district 
(P<0.001), and advanced WHO stage (P=0.003).
Conclusions—To sustain the obtained benefit of ART in this setting, interventions to improve 
nutritional status may be used as adjunct to ART.
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INTRODUCTION
Human immunodeficiency virus (HIV) infection is a major contributor of the global disease 
burden among children and adults. Globally, it is estimate that 2.5% of all child deaths are 
associated with HIV infection [1]. Africa remains the region most heavily affected, with 5% 
of all child deaths associated with HIV infection [1]. Introduction of antiretroviral therapy 
(ART) has reduced the mortality rates globally [2] through suppression of viral replication 
and HIV disease progression among patients receiving ART. ART access, particularly 
among children however, is still lagging. In addition, many of the low– and middle–income 
countries still face significant challenges, including higher mortality in the first few months 
following the initiation of ART [3,4]. There is scarcity of information on factors 
contributing to high mortality among Tanzanian children on ART despite the existence of 
the free ART program by the government since 2004.
Furthermore, mortality experience from studies of adults are not necessarily applicable to 
children for several reasons including possible in utero exposure to antiretroviral drugs 
(ARVs), differences in immunologic markers and levels among children of different age 
groups, and the continuing development and maturation of organ systems involved in 
immunity. However, a few studies have identified predictors of mortality among children 
infected with HIV who are initiating ART in Africa [4,5,6,7]. Some factors that have been 
related to the increased risk of death in adults and children include immune reconstitution 
inflammatory syndrome [8], undernutrition [4,5,6], anemia [7,9], severe immune 
suppression [10,11], and opportunistic infections including TB [12,13].
Identification of predictors of mortality among children initiating ART is critical in efforts to 
improve pediatric patients' outcomes. This study examined child undernutrition and other 
characteristics in relation to mortality among children < 15 years, initiating ART in the 
Management and Development for Health (MDH) program in Dar es Salaam, Tanzania from 
October 2004 through December 2010.
METHODS
Study Design, Setting and Participants
We performed a prospective cohort study among HIV–infected children initiating ART at 
MDH between October 2004 and December 2010. MDH is a Tanzanian–based non-
governmental organization supporting high quality HIV/AIDS care and treatment services in 
Dar es Salaam. The program was funded under the President's Emergency Plan for AIDS 
Relief (PEPFAR) as part of a Harvard School of Public Health initiative to provide ART 
access, management and care in Botswana, Nigeria and Tanzania. The program provides 
infrastructure, laboratory and technical support to HIV/AIDS Care and Treatment Centers 
and health facilities providing PMTCT and tuberculosis (TB) services in Dar es Salaam city 
and its suburbs.
All patients in this program received free routine care and treatment for HIV as per WHO–
approved guidelines designed by the Tanzania National AIDS Control Program (NACP) of 
the Ministry of Health and Social Welfare. Accordingly, Children were eligible for ART 
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when presented with a WHO clinical stage 4 or 3, irrespective of the absolute CD4+ cells 
count or percentage, or WHO stage 1 or 2 and severe immunodeficiency. In general, eligible 
children were initiated on one of the recommended first line ARV regimens which included 
at least two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and one non-
nucleoside reverse transcriptase inhibitor (NNRTI) or two NRTIs and one protease inhibitor 
(PI). Patients also received supportive care which included prophylaxis and treatment of 
opportunistic infections and other conditions. Eligible patients for this study were children 
age <15 years initiating ART.
Clinical procedures
Following enrollment, patients were evaluated monthly at the outpatient clinics. At each 
visit, they were examined by a physician, underwent adherence and nutrition counseling, 
and received ARV refills. Laboratory tests (complete blood count, liver function tests, serum 
creatinine and a lipid panel, and CD4+ cells) were performed every four months. 
Measurements of CD4+ cells count and percentage were obtained by standard flow 
cytometric methods with FacsCount or FacsCalibur machines. All children were screened 
for TB by a chest X-ray and sputum analysis at enrollment, and those found to have TB 
were treated according to the standard of care according to the Tanzania National TB and 
Leprosy control program guidelines.
Weight, height and mid-upper arm circumference (MUAC) were measured by trained 
nurses. Weight was measured to a nearest 0.1 Kg using electronic Seca scales (Seca 334 for 
children aged ≤5 years, and Seca 700 for children aged >5 years) with children wearing 
minimal clothing. Child height (recumbent length if less than 2 years of age) was measured 
using wooden height/length boards. MUAC was measured by tape measures.
Definition of outcomes
The primary endpoint for this study was all-cause mortality. Child deaths were either 
recorded following notification by family members, friends or the patient tracking team. 
Date and place of death were recorded, and if the date of death was unknown, the date of the 
last encounter with the patient was used as the day of death. Early mortality was defined as 
death occurring within the first 90 days following ARV initiation, and overall mortality was 
defined as death occurring at any point in time since ARV initiation.
Statistical Analysis
Standardized weight-for-age (WAZ), height/length-for-age (HAZ), weight-for-height/length 
(WHZ) Z-scores (for children 2 years or younger) and body mass index (BMIZ) Z-scores 
(for children above 2 years) were calculated using the WHO Child Growth Standard 
reference data [14]. Z scores were categorized into the following categories, >−1, −2< and ≤
−1, −3< and ≤−2, and ≤−3. A child was considered to be underweight, stunted, or wasted 
when WAZ, HAZ, or WHZ/BMIZ Z-score respectively was below −2 of the reference 
population. MUAC was conveniently categorized into >13.5 cm, 12.5 to 13.5cm, ≤11.5cm 
to <12.5cm, and <11.5cm. Using the WHO guidelines, children up to five years of age were 
classified as having low MUAC if they had MUAC <11.5cm. However, for children older 
than 5 years, a cut-off of 16.4cm (10th percentile) was adopted from NHANES (National 
Mwiru et al. Page 3
J Int Assoc Provid AIDS Care. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Health and Nutritional examination Survey) 2003–06 conducted by Centers for Disease 
Control (CDC), National Centre for Health Statistics (NCHS) for children older than 5 years 
[15].
Kaplan-Meier curves were used to estimate time to death in strata of child nutritional status. 
The association between baseline nutritional status, change in nutritional status within the 
first 90 days, and other baseline characteristics with mortality were examined using the Cox 
proportional hazards model for time to death with age of the child in years as the time scale. 
Children were censored at the end of study in December 2010 if they were event-free, or at 
their last visit. Cox proportional hazards models were run for the entire period of study, and 
for the first 90 days after ART initiation. Relative risks (hazard ratios), 95% confidence 
intervals, and corresponding P values were obtained from the models adjusting for potential 
confounders. Variables were included in the multivariate models if the estimated RR for 
their association with mortality was statistically significant at P ≤0.20 in the univariate 
analyses, or if they were a priori believed to be risk factors for mortality. Accordingly, these 
variables were adjusted for in the models; nutritional status, calendar year, level of immune 
suppression, WHO stage, history of TB, opportunistic infections, ARV regimen, district, 
cotrimoxazole use, season of ART initiation, and child's sex. The missing indicator method 
was used for missing data in categorical covariates. The criterion for significance for all the 
analyses was a P value significant at level of α = 0.05. All P values were 2 tailed. All 
statistical analyses were performed with the statistical software package SAS (version 9.2, 
SAS Institute Inc., Cary, NC).
The study was approved by the Institutional Review Board of the Harvard School of Public 
Health.
RESULTS
Between October 2004, and December 2010, 3180 children were initiated on ART. After 
excluding 36 children who had invalid or missing information on age, 3144 remained for 
this analysis, contributing a median of 17.2 months (interquartile range [IQR], 4.6–31.4 
months) of follow-up. Table 1 presents characteristics of the study participants at ART 
initiation. Briefly, the prevalence of child undernutrition at ART initiation was high, with 
53% of the children underweight, 33% wasted, 56% stunted and 39% had low MUAC. All 
the children were initiated on the recommended first line ARV regimens, with the majority 
of children (52%) put on a zidovudine plus lamuivudine plus nevirapine regimen.
Overall, 268 children died during the six years of follow up (six years cumulative mortality 
rate=12.4%). Of these, 151 (56.3%) children died within the first 90 days of ART initiation. 
The estimated cumulative mortality rates were 4.8%, 7.3%, 8.2%, and 8.5% at 3, 12, 24, and 
60 months following ART initiation respectively. The cumulative loss to follow-up rates at 
3, 12, 36, and 60 months after ART initiation were respectively, 10.6, 21.1, 30.8, and 58.2. 
Figure 1 presents the cumulative incidence of deaths by child WAZ and age at ART 
initiation. Death rates were highest among children with WAZ ≤−3 compared with those 
with WAZ >−1 (P<0.0001).
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The relationships between mortality and nutritional status after ART initiation are shown in 
Table 2. In the overall mortality, compared with children with WAZ score >−1, children 
with WAZ score from ≤−2 to <−3 had a nearly double risk of death (RR, 1.85 (95% CI, 
1.10–3.11), and those with severe underweight (WAZ ≤−3), the risk was more than tripled 
(RR, 3.36 (95% CI, 2.12–5.32). For deaths that occurred in the first 90 days after ART 
initiation, compared with children with WAZ score >−1, those with WAZ score from ≤−2 to 
<−3 had more than doubled risk of death (RR, 2.51 (95% CI, 1.05–5.95), and those with 
severe underweight (WAZ ≤−3), the risk more than 7-folds (RR, 7.12 (95% CI, 3.33–15.22). 
Similarly, WHZ and BMIZ scores of −2 or lower were associated with a significantly 
increased risk of mortality, more than double for the overall mortality and up to five-fold for 
mortality in the first 90 days of ART initiation. HAZ score of −1 or less on the other hand 
was associated with about two- to three-fold increased risk of early mortality and overall 
mortality. A MUAC of 13.5cm or less was associated with a two- to six-fold increased risk 
of early mortality as well as a two- to four-fold overall mortality.
The effects of other independent baseline risk factors for death are shown in table 3. The risk 
factors for death included severe anemia (RR, 1.91 (95% CI, 1.21–2.99); severe immune 
suppression (RR, 1.46 (95% CI, 1.07–2.00); history of TB (RR, 1.55 (95% CI, 1.09–2.18); 
having opportunistic infections (RR, 2.23 (95% CI, 1.61–3.09); living in the Temeke district 
of Dar es Salaam (RR, 1.58 (95% CI, 1.18–2.11), and advanced HIV disease stage (III and 
IV) at ART initiation [(RR, 1.85 (95% CI, 1.05–3.27) and (RR, 2.43 (95% CI, 1.33–4.42)] 
respectively. Child's sex, initial ART regimen, season of ART initiation and use of 
cotrimoxazole were not significantly associated with risk of mortality.
We next examined the associations of change in nutritional status by 3 months after ART 
initiation and mortality 3 months after ART initiation (Table 4). This analysis included the 
subset of 2993 children who survived past the first 90 days of ART initiation. There were 
117 deaths in total (mortality rate, 7.5%) after the first 90 days of ART initiation. Decline in 
WHZ or BMIZ score by more than 2SD was associated with a more than 3-fold increased 
risk of death (95% CI 1.63, 5.76). Similarly, a decline in HAZ score of more than 2SD was 
associated with a more than 2-fold increased risk of death (95% CI 1.09, 7.07). Decline in 
WAZ was not associated with a statistically significant increase in risk of death. A decline in 
MUAC of 1 cm or more was associated with an 84% increased risk of death (95% CI 1.24, 
2.75).
DISCUSSION
In this prospective study of children initiating ART in Tanzania, we found a mortality rate of 
12.4% over a median follow up time of 17.2 months. Mortality within the first 90 days of 
starting ART was found to be high in this study with more than 56% of deaths occurring in 
the first 90 days of ART initiation. These findings in the trend of mortality was consistent 
with findings from other studies in both low- and middle-income countries [3,4,9,16] 
although the mortality rate was slightly higher than the mortality rate of 8.3% reported over 
three years of follow up by Bolton-Moore and colleagues among 2938 children receiving 
ART in Zambia [4]. In this Zambian study, 1130 (38.5%) children were aged 59 months or 
younger while 1808 (61.3%) were 5 years or older. In contrast, 51% of the children in our 
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study were 5 years or younger which could partly explain the higher mortality rate we 
observed. Similar to our findings, of those who died in the Zambian cohort, 56.6% died 
within the first 90 days of starting ART. A study in Haiti, though of smaller sample size 
(n=236) and shorter duration of follow up (0–36 months) compared to our study, reported 
similar findings; overall mortality of 9% and 61% of deaths occurred within the first six 
months of ART [16]. In this study from Haiti, 13% of the children were younger than 18 
months old, 73% were between 1.5 and 12 years and only 13% were 13 years old or older.
A similar trend has also been reported in adults [9,17]. In a study among Tanzanian adult 
patients starting ART in the Manyara region, 62.1% of the patients who died during the 
follow up period, died within 3 months of starting ART [9]. Among patients receiving ART 
within the MDH program in Dar es Salam, Tanzania, Liu and colleagues reported that 79% 
of deaths occurred in the first 3 months after ART initiation [17].
We found that undernutrition at the time of ART initiation was associated with increased 
risk of mortality in this population of HIV-infected children. Children with low WAZ, HAZ 
and WHZ or BMIZ scores had increased risk of death. Even though there are some 
difficulties in comparing results from different studies due to differences in the definition of 
undernutrition in children, these results are similar to those reported previously by studies 
from similar resource limited settings [4,5,6,18]. In a large cohort of children in Zambia, 
mortality was associated with lower WAZ score among children younger than 5 years [4]. 
Another study in Uganda showed that children with lower WAZ score in the first year of life 
had increased risk of mortality by 25 months [5]. Similar associations between 
undernutrition and mortality have been reported in Malawi [6], South Africa [11], and 
Ethiopia [18].
Low MUAC is another measure of undernutrition that was significantly associated with an 
increased risk of mortality in this study. Similar findings have been reported in both children 
[19,20] and adult patients initiating ART in Tanzania [17].
Apart from food insecurity, symptoms of HIV disease such as anorexia, pain, nausea, 
vomiting, malabsorption, disease pathology, and diarrhea contribute to undernutrition in 
HIV-infected children. Furthermore, patients with opportunistic infections may have limited 
food intake and also increased resting energy expenditure leading to undernutrition. The 
result of all of these is often inadequate nutritional intake leading to the inability to maintain 
weight and lean tissue mass, and to micronutrient deficiency.
A history of TB and infections with other opportunistic infections were found to be 
associated with increased risk of mortality in this study. A few other studies have reported 
that TB and other opportunistic infections are the major causes of morbidity and mortality 
among HIV-infected patients even in the presence of ART. A study among patients 
receiving ART in Uganda found that baseline TB infection and non-TB opportunistic 
infections were significantly associated with increased risk of early as well as late mortality 
[12]. A recent study in South Africa reported that TB infection was associated with a 76% 
increased risk of death or loss to follow up [13]. Similarly, opportunistic infections increased 
the risk of death among patients receiving ART by up to 60% in a study in Uganda [21]. 
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Furthermore, TB or other opportunistic infections may increase the risk of death in the first 
few months after initiating ART due to immune reconstitution inflammatory syndrome 
(IRIS), a paradoxical worsening or recurrence of opportunistic infections symptoms as a 
result of rapid immunological recovery [8,22].
Anemia was a strong predictor of mortality in this cohort of children initiating ART. 
Children with severe anemia (hemoglobin<8.5g/dL) had an 87% increased risk of overall 
death compared to children who were not severely anemic. Several studies have shown that 
anemia is an independent risk factor for death in children and adults [4,6,7,9]. A study in 
Ethiopia [18] found that survival among children on ART was higher among children who 
had higher hemoglobin. Anemia may be multifactorial, and for this particular population, 
causes other than iron deficiency, such as malaria infection and hookworm infestation, may 
have stronger influence due to the endemicity of these conditions although we have no data 
to support this claim.
The association between socioeconomic status and mortality is a long recognized 
phenomenon. We found that living in the Temeke district of Dar es Salaam was associated 
with a 60% increased risk of death compared to living in Ilala. The district in which the 
patient lives is a proxy for the socioeconomic status of the patient since direct measurement 
of socioeconomic status was not undertaken in this study. The Temeke district is considered 
the poorest of the three districts of Dar es Salaam city.
We also found, as expected, that, severe immune suppression as evidenced by advanced 
HIV disease stage particularly stage III and IV or depleted CD4+ T-cells was associated 
with increased risk of death in this study. These findings are in line with those reported both 
in developed [18] and developing countries [4,11].
Decline in HAZ, WHZ and BMIZ scores in the first 3 months of ART was associated with 
increased risk of death after the first 90 days of ART initiation. These findings were 
consistent with those reported in adults [3,17]. However; it was not clear why only decrease 
in MUAC by 1cm or no change were associated with increased risk of death and not greater 
decreases in MUAC.
The major strengths of this study included the large sample size (3144 children) and long 
follow-up time (up to 6 years). Furthermore, since the study was population-based, the 
findings may be generalizable to HIV-infected children initiating ART in Tanzania as well 
as other countries in Sub-Saharan Africa. There are a number of limitations to this study 
however. We were unable to adjust for some potential confounders including maternal 
factors and viral load. In addition, there was high loss to follow up; 10.6%, 14.6%, 21.1% 
and 58.2% respectively at 3, 6, and 12 months, and overall. We looked at predictors of the 
combined endpoint of death or loss to follow and results were similar to findings for the 
overall mortality endpoint with only a few exceptions. It could therefore be argued that 
perhaps most of those who were lost to follow up did actually die, although we have no way 
to confirm that. Furthermore, we did not have data on causes of death.
In conclusion, undernutrition at the time of ART initiation was associated with increased 
risk of death, particularly during the first months after ART initiation. To sustain the 
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obtained benefit of ART in this setting, interventions to improve nutritional status should be 
considered as an adjunct to ART.
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Figure 1. 
Cumulative incidence of death by WAZ and age at antiretroviral therapy initiation. WAZ 
indicates weight-for-age Z score.
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Table 1
Demographic and clinical characteristics of HIV-infected children at the time of antiretroviral therapy (ART) 
initiation in Dar es Salaam, Tanzania between 2004–2010 (n = 3144)
Characteristic No. of subjects1 (%)
Age (years)
 0 – 2 927 (29)
 >2 – 5 687 (22)
 >5 1530 (49)
Sex
 Male 1562 (50)
 Female 1582 (50)
District of residence
 Ilala 1372 (44)
 Kinondoni 888 (29)
 Temeke 824 (27)
Year of ART initiation
 2004 – 2005 204 (6)
 2006 222 (7)
 2007 617 (20)
 2008 841 (27)
 2009 736 (23)
 2010 524 (17)
Underweight (weight-for-age z score <−2SD)
 Yes 1275 (53)
 No 1145 (47)
Wasting (weight-for-height z score <−2SD if ≤2 years; body-mass index z score <−2 SD if >2 years)
 Yes 990 (33)
 No 1976 (67)
Stunting (height-for-age z score <−2 SD)
 Yes 1673 (56)
 No 1323 (44)
Low mid-upper arm circumference (11.5cm if ≤5 years; 16.4 if >5years)2
 Yes 1222 (39)
 No 1880 (61)
Severe anemia (Hemoglobin <8.5g/dL)
 Yes 502 (23)
 No 1684 (77)
Severe immune suppression (CD4+ T-cells<15% if ≤5 years; <200 cells/μL if >5 years)3
 Yes 1035 (47)
 No 1160 (53)
WHO disease stage
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Characteristic No. of subjects1 (%)
 I 266 (11)
 II 481 (19)
 III 1540 (61)
 IV 225 (9)
History of tuberculosis
 Yes 612 (20)
 No 2472 (80)
Opportunistic infections4
 Yes 360 (11)
 No 2772 (89)
Use of Cotrimoxazole
 Yes 1580 (53)
 No 1390 (47)
ARV regimen5
 AZT/3TC/NVP 1075 (52)
 d4T/3TC/NVP 615 (30)
 AZT3TC/EFV 210 (10)
 d4T/3TC/EFV 146 (7)
 ABC/3TC/LPV 1 (0.05)
 ABC/3TC/NFV 1 (0.05)
ARV regimen
 Contains stavudine 761 (37)
 No stavudine 1287 (63)
ARV regimen
 Contains efavirenz 356 (17)
 No efavirenz 1692 (83)
1Numbers may not add up to 3144 due to missing values
2
There are no established mid-upper arm circumference cut-offs for children >5 years. The 16.4cm reference (10th percentile) was adopted from 
NHANES (National Health and Nutritional examination Survey) 2003–06 conducted by Centres for Disease Control (CDC), National Centre for 
Health Statistics (NCHS) (McDowell MA).
3Adopted from CDC. Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons – 2002. MMWR June 14, 2002 (CDC)
4
Patient having at least one or more of the following; herpes zoster, fungal infection, oral candidiasis, oral hairy leukoplakia, recurrent severe 
bacterial infection, pneumocystis jirovecii pneumonia, toxoplasmosis, cryptosporidiosis with diarrhea, cryptococcal meningitis, extrapulmonary 
TB, lymphoma, kaposis sarcoma, HIV encephalopathy
5AZT = Zidovudine, d4t = Stavudine, 3TC = Lamivudine, ABC = Abacavir, NVP = nevirapine, EFV = Efavirenz, NFV = Nelfinavir, LPV = 
lopinavir, Trimu = Triomune (d4t, 3TC, NVP)
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Table 2
Nutritional status in relation to mortality at different time periods after antiretroviral therapy initiation1,2
Anthropometric indices Mortality within the first 90 days Overall mortality
No. 
deaths/No. of 
children
RR (95% CI) P for trend No. 
deaths/No. 
of children
RR (95% CI) P for trend
Weight-for-age z score (WAZ) <0.001 <0.001
 WAZ > −1 8/528 1.00 24/528 1.00
 −2< WAZ ≤ −1 11/612 1.39 (0.55, 3.49) 27/612 1.13 (0.65, 1.97)
 −3 < WAZ ≤ −2 16/548 2.51 (1.05, 5.95) 39/548 1.85 (1.10, 3.11)
 WAZ≤ −3 116/1456 7.12 (3.33, 15.22) 178/1456 3.36 (2.12, 5.32)
Weight-for-height (WHZ) or body-
mass index (BMIZ) z score3
<0.001 <0.001
 WHZ > −1 29/1789 1.00 81/1789 1.00
 −2< WHZ ≤ −1 8/181 0.90 (0.40, 2.04) 12/181 0.58 (0.31, 1.09)
 −3 < WHZ ≤ −2 21/457 2.25 (1.27, 3.99) 51/457 2.09 (1.46, 3.00)
 WHZ≤ −3 93/717 5.80 (3.65, 9.22) 124/717 2.94 (2.14, 4.03)
Height-for-age z score (HAZ) <0.001 <0.001
 HAZ > −1 18/598 1.00 32/598 1.00
 −2< HAZ ≤ −1 27/722 1.90 (1.03, 3.50) 54/722 1.92 (1.23, 3.00)
 −3 < HAZ ≤ −2 32/756 2.09 (1.14, 3.82) 54/756 1.80 (1.14, 2.82)
 HAZ ≤ −3 74/1068 3.69 (2.11, 6.45) 128/1068 3.03 (2.00, 4.60)
Mid-Upper Arm Circumference 
(MUAC)
<0.001 <0.001
 MUAC>13.5 36/1962 1.00 85/1962 1.00
 12.5–13.5 25/484 2.48 (1.41, 4.36) 48/484 1.97 (1.34, 2.89)
27/292 3.55 (1.99, 6.31) 40/292 2.28 (1.49, 3.49)
11.5≤MUAC<12.5 63/406 6.29 (3.62, 10.96) 95/406 3.87 (2.63, 5.70)
 MUAC<11.5
1Cox proportional hazards model with age as time scale
2Adjusted for calendar year (categorized as 2004–2005, 2006, 2007, 2008, 2009, 2010), hemoglobin level (categorized as HB>11, 8.5–11, <8.5g/
dL), immune suppression (categorized as severe, CD4+ T-cells<15% if ≤5 years; <200 cells/μL if >5 years and non severe), HIV disease stage 
(categorized as I, II, II and IV), history of TB (yes vs. no), opportunistic infections (yes vs. no), ARV regimen containing EFV (yes vs. no), district 
(Ilala, Kinondoni and Temeke), cotrimoxazole use (yes vs. no) and season at ART initiation (categorized as long dry, short dry, long rainy, short 
rainy) and sex
3WHZ for children ≤2 years and BMIZ for children >2 years
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Table 3
Baseline characteristics in relation to overall mortality after antiretroviral therapy initiation1
Predictor No. deaths/No. of children Univariate Multivariate2
RR (95% CI) P for trend RR (95% CI) P for trend
Sex 0.03 0.10
 Female 116/1582 1.00 1.00
 Male 152/1562 1.31 (1.03, 1.67) 1.23 (0.96, 1.57)
District of ART initiation <0.001 <0.001
 Ilala 103/1372 1.00 1.00
 Kinondoni 58/888 0.84 (0.61, 1.16) 0.81 (0.58, 1.12)
 Temeke 107/884 1.56 (1.19, 2.05) 1.58 (1.18, 2.11)
ARV regimen 0.01 0.11
 Contains stavudine 68/761 1.58 (1.14, 2.19) 1.32 (0.94, 1.84)
 No stavudine 95/1287 1.00 1.00
Use of Cotrimoxazole 0.43 0.59
 No 138/1564 1.00 1.00
 Yes 130/1580 1.09 (0.85, 1.40) 0.93 (0.71, 1.21)
Hemoglobin at ART initiation <0.001 <0.001
 HB>11 23/403 1.00 1.00
 8.5–11 89/1281 1.06 (0.67, 1.68) 0.98 (0.61, 1.56)
 HB<8.5 156/1460 2.09 (1.34, 3.26) 1.91 (1.21, 2.99)
Severe immune 0.01 0.02
suppression3 1.00 1.00
 No 178/2109 1.67 (1.23, 2.28) 1.46 (1.07, 2.00)
 Yes 90/1035
HIV disease stage <0.001 0.003
 I 16/266 1.00 1.00
 II 27/481 2.30 (1.22, 4.35) 1.63 (0.85, 3.12)
 III 126/1540 3.70 (2.15, 6.35) 1.85 (1.05, 3.27)
 IV 99/857 3.71 (2.14, 6.45) 2.43 (1.33, 4.42)
History of TB 0.01 0.01
 No 213/2532 1.00 1.00
 Yes 55/612 1.61 (1.17, 2.22) 1.55 (1.09, 2.18)
Opportunistic infections4 <0.001 <0.001
 No 213/2532 1.00 1.00
 Yes 55/612 2.24 (1.66, 3.02) 2.23 (1.61, 3.09)
1Cox proportional hazards model with age as time scale
2Adjusted for weight-for-age Z score (categorized as WAZ > −1, −2< WAZ ≤−1, −3 < WAZ ≤ −2, WAZ≤ −3), calendar year (categorized as 
2004–2005, 2006, 2007, 2008, 2009, 2010), hemoglobin level (categorized as HB>11, 8.5–11, <8.5g/dL), immune suppression (categorized as 
severe, CD4+ T-cells<15% if ≤5 years; <200 cells/μL if >5 years and non severe), HIV disease stage (categorized as I, II, II and IV), history of TB 
(yes vs. no), opportunistic infections (yes vs. no), ARV regimen containing EFV (yes vs. no), district (Ilala, Kinondoni and Temeke), cotnmoxazole 
use (yes vs. no) and season at ART initiation (categorized as long dry, short dry, long rainy, short rainy) and sex
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3CD4+ T-cells<15% if ≤5 years; <200 cells/μL if >5 years
4
Patient having at least one or more of the following; herpes zoster, fungal infection, oral candidiasis, oral hairy leukoplakia, recurrent severe 
bacterial infection, pneumocystis jirovecii pneumonia, toxoplasmosis, cryptosporidiosis with diarrhea, cryptococcal meningitis, extrapulmonary 
TB, lymphoma, kaposis sarcoma, HIV encephalopathy
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Table 4
Change in nutritional status within the first three months of antiretroviral therapy initiation in relation to 
mortality after 3 months1
Change in Anthropometric indices No. deaths/No. of 
children
Univariate Multivariate2
RR (95% CI) P for trend RR (95% CI) P for trend
Weight-for-age z score Change 0.11 0.07
Decline by >2 SD 16/520 2.00 (0.62, 6.42) 1.87 (0.56, 6.18)
Decline by >1 to 2 SD 16/601 1.54 (0.66, 3.57) 1.84 (0.78, 4.34)
Decline by 0 to 1 SD 23/532 1.21 (0.77, 1.90) 1.27 (0.80, 2.02)
Any increase 62/1340 1.00 1.00
Weight-for-height (WHZ) or Body-Mass Index 
(BMIZ) z score change3
0.01 0.003
 Decline >2 SD 52/1760 2.93 (1.58, 5.45) 3.06 (1.63, 5.76)
 Decline by >1 to 2 SD 4/173 0.78 (0.32, 1.94) 0.90 (0.36, 2.24)
 Decline by 0 to 1 SD 30/436 1.43 (0.91, 2.23) 1.57 (0.99, 2.50)
 Any increase 31/624 1.00 1.00
Height-for-age Z-score change
Decline by >2 SD 14/580 2.33 (0.93, 5.84) 0.46 2.78 (1.09, 7.07) 0.21
Decline by >1 to 2 SD 27/695 0.56 (0.20, 1.55) 0.62 (0.22, 1.74)
Decline by 0 to 1SD 22/724 1.18 (0.80, 1.73) 1.29 (0.87, 1.93)
Any increase 54/994 1.00 1.00
Mid-Upper Arm Circumference change 0.02 0.02
Decline by >2 cm 49/1926 2.05 (0.83, 5.10) 1.94 (0.76, 4.96)
Decline by >1 to 2 cm 23/459 1.01 (0.37, 2.77) 1.05 (0.38, 2.92)
Decline by 0 to 1 cm 13/265 1.71 (1.16, 2.52) 1.84 (1.24, 2.75)
Any increase 32/343 1.00 1.00
1Cox proportional hazards model with age as time scale
2Adjusted for calendar year (categorized as 2004–2005, 2006, 2007, 2008, 2009, 2010), hemoglobin level (categorized as HB>11, 8.5–11, <8.5g/
dL), immune suppression (categorized as severe, CD4+ T-cells<15% if ≤5 years; <200 cells/μL if >5 years and non severe), HIV disease stage 
(categorized as I, II, II and IV), history of TB (yes vs. no), opportunistic infections (yes vs. no), ARV regimen containing EFV (yes vs. no), district 
(Ilala, Kinondoni and Temeke), cotrimoxazole use (yes vs. no) and season at ART initiation (categorized as long dry, short dry, long rainy, short 
rainy) and sex
3WHZ for children ≤2 years and BMIZ for children >2 years
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